



12 AI + Health Stocks to Watch in 2025

Early-stage names • Compute dependencies • Risk profiles

Overview

The intersection of **artificial intelligence and healthcare** is one of the fastest-growing frontiers in technology. This guide highlights **12 promising AI-Health companies** positioned for growth in 2025 — from drug discovery to diagnostics and medical robotics.

Each profile includes:

- **Ticker + Exchange**
 - **Core AI Use Case**
 - **Compute Dependency (High / Moderate / Low)**
 - **Key Partners / Cloud Providers**
 - **Risk Profile (1–5)**
 - **Rabbt Take (1-line summary)**
-

SECTION 1 — AI in Biotech & Drug Discovery

Company	Ticker	Focus	Compute Dependency	Risk	Rabbt Take
Recursion Pharmaceuticals	RXRX	AI-driven drug discovery	High	3/5	Backed by Nvidia; strong data pipelines, but long path to profitability.
Exscientia plc	EXAI	AI molecule design	High	4/5	High innovation; regulatory headwinds may slow revenue scaling.
Insilico Medicine	Private	Generative drug design	High	5/5	Private leader—IPO potential late 2025. Watch closely.
Schrödinger, Inc.	SDGR	Simulation-based molecule modeling	Moderate	3/5	Hybrid SaaS + pharma model gives balanced upside.

SECTION 2 — AI Diagnostics & Imaging

Company	Ticker	Focus	Compute Dependency	Risk	Rabbt Take
Tempus AI	TEM	Genomic data + clinical AI	High	3/5	Recently public; leading U.S.

Company	Ticker	Focus	Compute Dependency	Risk	Rabbt Take
					precision-medicine data play.
Butterfly Network	BFLY	AI handheld ultrasound	Moderate	4/5	Attractive hardware margins, but adoption pace is slow.
Nanox Imaging	NNOX	AI X-ray systems	Moderate	5/5	Speculative bet; regulatory and manufacturing risks remain.

SECTION 3 – AI in Patient Monitoring & Devices

Company	Ticker	Focus	Compute Dependency	Risk	Rabbt Take
iRhythm Technologies	IRTC	AI cardiac monitoring	Moderate	3/5	Market leader in arrhythmia detection with steady reimbursement growth.
AliveCor (Private)		AI ECG analysis	Low	4/5	Apple Watch integration could accelerate visibility.

Masimo Corporation	MASI	Sensor-based AI health tracking	Low	2/5	Steady hardware growth; under-valued given IP strength.
---------------------------	------	---------------------------------	-----	-----	---

SECTION 4 – AI Platforms & Infrastructure Behind Health AI

Company	Ticker	Focus	Compute Dependency	Risk	Rabbt Take
Nvidia Corporation	NVDA	AI compute backbone for bioinformatics	Very High	2/5	The silent power behind most health-AI workloads.
Palantir Technologies	PLTR	AI data integration for health systems	High	3/5	Growing federal + hospital contracts; sticky enterprise client base.

Summary Snapshot

Category	Average Risk	Notable Theme
Drug Discovery	3.75 / 5	Generative AI race heats up
Diagnostics	4.0 / 5	FDA bottlenecks remain key limiter
Monitoring Devices	3.0 / 5	Hardware AI integration deepens

Category	Average Risk	Notable Theme
Infrastructure	2.5 / 5	Compute leaders drive margins

Rabbt Insights Perspective

The AI + Health sector is **transitioning from hype to hard data**.

2025 will separate platform builders (like Nvidia, Tempus, and Palantir) from speculative biotech AI plays still burning cash.

Our take:

Hold long-term exposure in infrastructure, trade high-beta diagnostics selectively.

How to Use This Guide

1. Use this list as a **watchlist** in Yahoo Finance or TradingView.
2. Monitor **clinical milestones** and **FDA clearances** quarterly.
3. Compare each stock's **compute exposure** — the higher the GPU reliance, the more likely short-term volatility tied to Nvidia trends.
4. Revisit this list every quarter — we'll update it via Rabbt Premium.

Coming soon: Join Rabbt Premium for deeper analysis, live charts, and private Discord access.